SageView Advisory Group LLC Makes New Investment in Sanofi (NASDAQ:SNY)

SageView Advisory Group LLC acquired a new position in Sanofi (NASDAQ:SNY - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 6,227 shares of the company's stock, valued at approximately $300,000.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Arkadios Wealth Advisors boosted its position in shares of Sanofi by 19.0% in the 4th quarter. Arkadios Wealth Advisors now owns 4,709 shares of the company's stock worth $227,000 after buying an additional 751 shares in the last quarter. Geode Capital Management LLC grew its position in shares of Sanofi by 7.1% in the third quarter. Geode Capital Management LLC now owns 254,738 shares of the company's stock valued at $14,681,000 after purchasing an additional 16,780 shares during the last quarter. JPMorgan Chase & Co. increased its stake in shares of Sanofi by 20.9% during the 3rd quarter. JPMorgan Chase & Co. now owns 2,310,809 shares of the company's stock worth $133,172,000 after purchasing an additional 399,301 shares in the last quarter. Kentucky Trust Co purchased a new position in Sanofi during the fourth quarter worth $436,000. Finally, World Investment Advisors LLC lifted its position in shares of Sanofi by 1,020.5% in the third quarter. World Investment Advisors LLC now owns 48,430 shares of the company's stock valued at $2,791,000 after acquiring an additional 44,108 shares in the last quarter. Institutional investors and hedge funds own 14.04% of the company's stock.

Analysts Set New Price Targets

A number of research firms recently commented on SNY. Sanford C. Bernstein upgraded Sanofi to a "strong-buy" rating in a research report on Thursday, January 30th. BNP Paribas began coverage on shares of Sanofi in a report on Tuesday, April 15th. They set an "outperform" rating and a $65.00 price target for the company. The Goldman Sachs Group assumed coverage on shares of Sanofi in a research note on Friday, March 21st. They set a "neutral" rating and a $65.00 price objective on the stock. Finally, Deutsche Bank Aktiengesellschaft upgraded shares of Sanofi from a "sell" rating to a "hold" rating in a research report on Thursday, January 30th. Three equities research analysts have rated the stock with a hold rating, two have issued a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $63.33.

Sanofi Trading Up 0.0 %

SNY traded up $0.02 during midday trading on Monday, hitting $50.92. The company's stock had a trading volume of 272,203 shares, compared to its average volume of 2,342,602. Sanofi has a 52-week low of $45.80 and a 52-week high of $60.12. The firm has a 50-day moving average price of $54.73 and a two-hundred day moving average price of $52.14. The company has a current ratio of 1.46, a quick ratio of 1.14 and a debt-to-equity ratio of 0.15. The firm has a market cap of $128.62 billion, a P/E ratio of 20.47, a PEG ratio of 1.01 and a beta of 0.57.

Sanofi (NASDAQ:SNY - Get Free Report) last released its earnings results on Thursday, January 30th. The company reported $0.70 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. On average, research analysts anticipate that Sanofi will post 4.36 earnings per share for the current year.

Sanofi Increases Dividend

The company also recently announced an annual dividend, which will be paid on Thursday, June 12th. Investors of record on Friday, May 9th will be issued a $2.0369 dividend. The ex-dividend date of this dividend is Friday, May 9th. This represents a yield of 3.1%. This is a boost from Sanofi's previous annual dividend of $1.48. Sanofi's dividend payout ratio (DPR) is presently 64.26%.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.